Naproxen: Difference between revisions
ClaireLewis (talk | contribs) (Created page with "==Administration== *Type: NSAID *Dosage Forms: *Routes of Administration: PO *Common Trade Names: Aleve ==Adult Dosing== *500mg PO BID OR 250mg q6-8h ==Pediatric Dosing==...") |
Elcatracho (talk | contribs) |
||
| (5 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
==Administration== | ==Administration== | ||
*Type: [[NSAID]] | *Type: [[NSAID]] | ||
*Dosage Forms: | *Dosage Forms: 250mg, 500mg | ||
*Routes of Administration: PO | *Routes of Administration: PO | ||
*Common Trade Names: Aleve | *Common Trade Names: Aleve | ||
==Adult Dosing== | ==Adult Dosing== | ||
*500mg PO BID OR 250mg q6-8h | *500mg PO BID '''OR''' 250mg q6-8h | ||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
* | *5mg/kg BID | ||
==Special Populations== | ==Special Populations== | ||
*[[Drug Ratings in Pregnancy|Pregnancy Rating]]: C | *[[Drug Ratings in Pregnancy|Pregnancy Rating]]: C | ||
| Line 29: | Line 29: | ||
*Angioedema | *Angioedema | ||
*Bronchospasm | *Bronchospasm | ||
*CHF, pulmonary edema | *[[CHF]], pulmonary edema | ||
*Thrombocytopenia, aplastic anemia, hemolytic anemia, agranulocytosis | *Thrombocytopenia, aplastic anemia, hemolytic anemia, agranulocytosis | ||
*Vasculitis | *Vasculitis | ||
| Line 53: | Line 53: | ||
==See Also== | ==See Also== | ||
*[NSAIDs] | *[[NSAIDs]] | ||
*[[NSAID toxicity]] | |||
==References== | ==References== | ||
<references/> | <references/> | ||
[[Category:Pharmacology]] | [[Category:Pharmacology]] | ||
Latest revision as of 22:46, 7 March 2021
Administration
- Type: NSAID
- Dosage Forms: 250mg, 500mg
- Routes of Administration: PO
- Common Trade Names: Aleve
Adult Dosing
- 500mg PO BID OR 250mg q6-8h
Pediatric Dosing
- 5mg/kg BID
Special Populations
- Pregnancy Rating: C
- Lactation risk: infant risk minimal
Renal Dosing
- Adult: Not recommended if CrCl <30
- Pediatric:
Hepatic Dosing
- Adult: use lowest effective dose
- Pediatric:
Contraindications
- Allergy to class/drug
- peri-CABG
Adverse Reactions
Serious
- GI bleed, gastric ulcer
- Nephrotoxicity
- Angioedema
- Bronchospasm
- CHF, pulmonary edema
- Thrombocytopenia, aplastic anemia, hemolytic anemia, agranulocytosis
- Vasculitis
- SJS/TEN
- Hepatotoxicity (hepatitis, liver failure)
- Aseptic meningitis, seizure
Common
- Nausea, heartburn, constipation
- Edema
- Ecchymosis
- Headache
- Ototoxicity
Pharmacology
- Half-life: 12-17 hours
- Metabolism:
- Excretion: Renal
Mechanism of Action
- NSAID